These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35959378)

  • 21. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.
    Mi J; Gong W; Wu X
    Biomed Res Int; 2022; 2022():5099312. PubMed ID: 35252448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs.
    Jo EK
    Curr Opin Infect Dis; 2008 Jun; 21(3):279-86. PubMed ID: 18448973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating Multifaceted Information to Predict Mycobacterium tuberculosis-Human Protein-Protein Interactions.
    Sun J; Yang LL; Chen X; Kong DX; Liu R
    J Proteome Res; 2018 Nov; 17(11):3810-3823. PubMed ID: 30269499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery.
    Cazzaniga G; Mori M; Chiarelli LR; Gelain A; Meneghetti F; Villa S
    Eur J Med Chem; 2021 Nov; 224():113732. PubMed ID: 34399099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dectin-1-Syk-CARD9 Signaling Pathway in TB Immunity.
    Wagener M; Hoving JC; Ndlovu H; Marakalala MJ
    Front Immunol; 2018; 9():225. PubMed ID: 29487599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural and trained innate immunity against Mycobacterium tuberculosis.
    Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
    Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pattern recognition receptors and coordinated cellular pathways involved in tuberculosis immunopathogenesis: Emerging concepts and perspectives.
    Mishra A; Akhtar S; Jagannath C; Khan A
    Mol Immunol; 2017 Jul; 87():240-248. PubMed ID: 28514713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lung Epithelial Signaling Mediates Early Vaccine-Induced CD4
    Das S; Marin ND; Esaulova E; Ahmed M; Swain A; Rosa BA; Mitreva M; Rangel-Moreno J; Netea MG; Barreiro LB; Divangahi M; Artyomov MN; Kaushal D; Khader SA
    mBio; 2021 Aug; 12(4):e0146821. PubMed ID: 34253059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut Microbiota Regulates Mincle Mediated Activation of Lung Dendritic Cells to Protect Against
    Negi S; Pahari S; Bashir H; Agrewala JN
    Front Immunol; 2019; 10():1142. PubMed ID: 31231363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innate immune recognition of Mycobacterium tuberculosis.
    Kleinnijenhuis J; Oosting M; Joosten LA; Netea MG; Van Crevel R
    Clin Dev Immunol; 2011; 2011():405310. PubMed ID: 21603213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Yang L; Hu X; Chai X; Ye Q; Pang J; Li D; Hou T
    Drug Discov Today; 2022 Jan; 27(1):326-336. PubMed ID: 34537334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distinct Strategies Employed by Dendritic Cells and Macrophages in Restricting Mycobacterium tuberculosis Infection: Different Philosophies but Same Desire.
    Khan N; Vidyarthi A; Pahari S; Agrewala JN
    Int Rev Immunol; 2016 Sep; 35(5):386-398. PubMed ID: 25793750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug targeting of heme proteins in Mycobacterium tuberculosis.
    McLean KJ; Munro AW
    Drug Discov Today; 2017 Mar; 22(3):566-575. PubMed ID: 27856345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uncovering the Mast Cell Response to
    Torres-Atencio I; Campble A; Goodridge A; Martin M
    Front Immunol; 2022; 13():886044. PubMed ID: 35720353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pasakbumin A controls the growth of Mycobacterium tuberculosis by enhancing the autophagy and production of antibacterial mediators in mouse macrophages.
    Lee HJ; Ko HJ; Kim SH; Jung YJ
    PLoS One; 2019; 14(3):e0199799. PubMed ID: 30865638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Fatty Acid Oxidation Promotes Macrophage Control of Mycobacterium tuberculosis.
    Chandra P; He L; Zimmerman M; Yang G; Köster S; Ouimet M; Wang H; Moore KJ; Dartois V; Schilling JD; Philips JA
    mBio; 2020 Jul; 11(4):. PubMed ID: 32636249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NOD-2 and TLR-4 Signaling Reinforces the Efficacy of Dendritic Cells and Reduces the Dose of TB Drugs against Mycobacterium tuberculosis.
    Khan N; Pahari S; Vidyarthi A; Aqdas M; Agrewala JN
    J Innate Immun; 2016; 8(3):228-42. PubMed ID: 26613532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents.
    Evans JC; Mizrahi V
    Curr Opin Microbiol; 2018 Oct; 45():39-46. PubMed ID: 29482115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoarabinomannan, and its related glycolipids, induce divergent and opposing immune responses to Mycobacterium tuberculosis depending on structural diversity and experimental variations.
    Källenius G; Correia-Neves M; Buteme H; Hamasur B; Svenson SB
    Tuberculosis (Edinb); 2016 Jan; 96():120-30. PubMed ID: 26586646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.